Skip to search formSkip to main contentSkip to account menu

refractory hairy cell leukemia

Known as: Hairy Cell Leukemia, Refractory, leukemia, hairy cell, recurrent, recurrent hairy cell leukemia 
Hairy cell leukemia that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

18 relations
Atypical lymphocyteB lymphoblastB-LymphocytesBRAF gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Moxetumomab pasudotox-tdfk is a first-in-class recombinant CD22-directed cytotoxin approved in the US for the treatment of adult… 
2018
2018
Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and…
7060Background: Moxe is an immunotoxin targeting CD22 on B cells leading to cell death. The objectives of this analysis were to… 
Review
2015
Review
2015
Immunoconjugates in the management of hairy cell leukemia.
2014
2014
Treatment of Refractory Hairy Cell Leukemia with a BRAF-inhibitor: Lessons to be Learnt
Hairy cell leukemia is a rare chronic lymphoproliferative disorder with indolent but progressive clinical course. Patients… 
2012
2012
Targeted immunotherapy for hairy cell leukemia.
In Journal of Clinical Oncology, Kreitman et al report the efficacy of anti-CD22 monoclonal antibody (mAb) conjugated to… 
Review
2011
Review
2011
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
Standard treatment for hairy cell leukemia (HCL) is markedly effective, but the constant decrease in disease-free survival… 
2010
2010
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results
Abstract 2516 Currently no adequate therapies exist for patients with refractory hairy cell leukemia (HCL). The CD22 antigen is… 
Review
2006
Review
2006
Immunotoxins in the treatment of refractory hairy cell leukemia.
2005
2005
[Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress].
A 69-year-old man was referred to our hospital because of thrombocytopenia and was diagnosed as having hairy cell leukemia… 
2004
2004
Successful Induction of Long-Term Remission Using Rituximab in a Patient with Refractory Hairy Cell Leukemia—Japanese Variant
We report the case of a 76-year-old man with hairy cell leukemia (HCL)-Japanese variant who underwent rituximab therapy. HCL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)